Form 4: Procept BioRobotics EVP Alaleh Nouri Reports Stock Option Exercises and Sales
SEC Form 4
Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics, reports exercising stock options and selling shares on May 3, 2024.
Summary
- On May 3, 2024, Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics Corp [PRCT], executed multiple transactions involving the company's common stock.
- Nouri exercised stock options to acquire a total of 30,432 shares at prices of $4.56, $5.18, and $7.27 per share.
- Concurrently, Nouri sold a total of 30,022 shares of common stock at prices ranging from $60.84 to $64.04.
- Following these transactions, Nouri directly owns 62,472 shares of Procept BioRobotics Corp.
- Nouri also holds derivative securities in the form of stock options, with 32,894 options remaining after the reported transactions.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing represents routine transactions. The sale of shares is balanced by the exercise of options.
Positives
- The exercise of stock options demonstrates Nouri's confidence in the company's future prospects.
Negatives
- The sale of shares by Nouri could be interpreted as a lack of confidence, although it could also be for personal financial planning.
Risks
- Significant stock sales by company executives can sometimes negatively impact investor sentiment.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in financial analysis to gauge executive sentiment and potential future performance.
- Comparing Nouri's transactions to those of other executives in similar roles at comparable medical device companies could provide further context.
Stakeholder Impact
- Shareholders may react to the insider selling activity, although the impact is likely to be minimal given the routine nature of the filing.
Key Dates
| Date | Description |
|---|---|
| 12/12/2019 | Date of grant for 1,467 stock options, vesting monthly over four years. |
| 08/10/2020 | Date of grant for 3,965 stock options, vesting 12.5% after six months and the remainder monthly over three and a half years. |
| 06/22/2021 | Date of grant for 25,000 stock options, vesting 25% after six months and the remainder monthly over four years. |
| 05/03/2024 | Date of stock option exercises and sales reported in the Form 4. |
| 12/11/2029 | Expiration date for 1,467 stock options granted on December 12, 2019. |
| 08/08/2030 | Expiration date for 3,965 stock options granted on August 10, 2020. |
| 06/21/2031 | Expiration date for 25,000 stock options granted on June 22, 2021. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.